About This Interactive Guideline
This tool is designed to provide healthcare professionals with a streamlined, interactive way to navigate the official COVID-19 treatment guideline. By selecting key patient characteristics, the tool generates the recommended therapeutic management strategy and provides key drug dosing information based on the latest evidence from organizations like the NIH and IDSA.
Key Medication Dosing & Administration
Nirmatrelvir/ritonavir (Paxlovid)
- Standard Dose: 300 mg nirmatrelvir with 100 mg ritonavir, taken together orally twice daily for 5 days.
- Renal Dosing (eGFR ≥30 to <60 mL/min): Reduce dose to 150 mg nirmatrelvir with 100 mg ritonavir, taken together twice daily for 5 days.
- Severe renal impairment (eGFR <30 mL/min): Not recommended — an appropriate dose has not been established (per the FDA label).
- Contraindications: hypersensitivity, and co-administration with drugs highly dependent on CYP3A for clearance where elevated concentrations could cause serious reactions; also avoid in severe hepatic impairment. Always screen for drug–drug interactions.
Remdesivir (Veklury)
- Standard Adult Dose: A single loading dose of 200 mg IV on Day 1, followed by a once-daily maintenance dose of 100 mg IV on subsequent days.
- Total Duration: 5 days for most hospitalized patients; up to 10 days for patients on invasive mechanical ventilation/ECMO or with no clinical improvement.
- Administration: Infuse intravenously over 30 to 120 minutes after proper reconstitution and dilution.
Dexamethasone
- Standard Adult Dose: 6 mg once daily, either intravenously (IV) or orally (PO), for up to 10 days or until hospital discharge, whichever comes first.
- Indication: For use in patients who are hospitalized and require supplemental oxygen. It is not recommended for patients who do not require oxygen.
Monoclonal Antibodies & Immunomodulators
Anti-SARS-CoV-2 monoclonal antibodies (e.g., bebtelovimab, sotrovimab) are not currently recommended for treatment, because circulating variants are resistant and their authorizations have been withdrawn. When an immunomodulator (baricitinib or tocilizumab) is used for severe or critical disease, it should be given together with a corticosteroid; the 2025 IDSA update expresses a preference for baricitinib.
Frequently Asked Questions (FAQ)
1. Who is considered “high risk” for progression to severe COVID-19?
High-risk factors include older age (e.g., >65 years), being unvaccinated, and the presence of underlying conditions such as obesity, diabetes, chronic kidney disease, significant heart or lung disease, and immunocompromising conditions.
2. What is “Paxlovid Rebound”?
Paxlovid rebound refers to a recurrence of COVID-19 symptoms or a new positive viral test 2 to 8 days after completing the 5-day treatment course. It is generally mild and does not typically require additional antiviral treatment, but patients should re-isolate according to public health recommendations.
3. When should immunomodulators like Baricitinib or Tocilizumab be used?
They are reserved for hospitalized patients with evidence of systemic inflammation and rapidly increasing oxygen needs. They are used in addition to Dexamethasone to provide further anti-inflammatory effects and have been shown to reduce mortality in specific patient populations.
4. Can these treatments be used during pregnancy?
Treatment decisions during pregnancy are complex. Paxlovid and Remdesivir may be considered if the potential benefits outweigh the risks. Molnupiravir is not recommended. This decision requires a careful discussion between the clinical team and the patient.
5. What if a patient’s condition worsens during treatment?
The COVID-19 treatment guideline is dynamic. If an outpatient’s condition worsens, they may need hospitalization. If a hospitalized patient’s oxygen needs increase, their treatment may need to be escalated (e.g., by adding an immunomodulator). Continuous monitoring is essential.
Related Calculators
📖 Sources:
- Shumaker, A. H., et al. (2026). 2025 Clinical Practice Guideline Update by the IDSA on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults. Clinical Infectious Diseases.
- Infectious Diseases Society of America (IDSA). Guidelines on the Treatment and Management of Patients with COVID-19 (living guideline).
- World Health Organization (WHO). Therapeutics and COVID-19: Living Guideline (2025).
- National Institutes of Health (NIH). COVID-19 Treatment Guidelines (archived; final update February 2024).
- Hammond, J., et al. (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 (EPIC-HR). New England Journal of Medicine, 386(15), 1397-1408.
- RECOVERY Collaborative Group. (2021). Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 384(8), 693-704.
- Beigel, J. H., et al. (2020). Remdesivir for the Treatment of Covid-19 — Final Report (ACTT-1). New England Journal of Medicine, 383(19), 1813-1826.
- RECOVERY Collaborative Group. (2021). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY). Lancet, 397(10285), 1637-1645.
- Marconi, V. C., et al. (2021). Efficacy and safety of baricitinib for hospitalised adults with COVID-19 (COV-BARRIER). Lancet Respiratory Medicine, 9(12), 1407-1418.
⚠️ Disclaimer:
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context. This COVID-19 treatment guideline tool is a reference, not a prescription.
